Literature DB >> 33296271

Targeted Screening for HIV Pre-Exposure Prophylaxis Eligibility in Two Emergency Departments in Washington, DC.

Paige Kulie1, Amanda D Castel2, Zhaonian Zheng3, Natasha N Powell1, Aneil Srivastava1, Sandhya Chandar1, Melissa L McCarthy1,3.   

Abstract

Pre-exposure prophylaxis (PrEP) is an effective method to prevent HIV acquisition in high-risk individuals. This cross-sectional survey study estimated the proportion of patients who were PrEP eligible among a targeted sample of emergency department (ED) patients with chief complaints indicative of HIV risk. Research assistants screened a convenience sample of adult patients who presented to two hospital EDs in Washington, DC, during a 6-month period with genitourinary, substance use, or intentional injury-related complaints. Patients with these complaints who reported being sexually active within the past 6 months and HIV negative completed a computer-assisted survey that included questions on sexual practices and partners, substance use, and attitudes and knowledge about PrEP. We used the Centers for Disease Control and Prevention (CDC) clinical guidelines to determine whether PrEP use was indicated. We report differences in PrEP eligibility by demographic characteristics, knowledge, and attitudes. Of the 410 participants, the majority were black (85%), and heterosexual females (72%). PrEP use was indicated in 20% (N = 84), most commonly because of condomless sex with a person of unknown HIV status (82%) and/or a sexually transmitted infection (STI) diagnosis (41%). One-third (34%) of participants had heard of PrEP. Overall, 36% of the sample (N = 148) wanted to learn more about PrEP while in the ED. The percentage who wanted to learn more about PrEP was higher among PrEP-eligible patients (52%) compared with PrEP-ineligible patients (32%). Using CDC criteria, targeted screening identified that a substantial proportion of ED patients are PrEP eligible based on their self-reported behaviors.

Entities:  

Keywords:  HIV; emergency medicine; pre-exposure prophylaxis; prevention; screening

Year:  2020        PMID: 33296271     DOI: 10.1089/apc.2020.0228

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  5 in total

Review 1.  US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review.

Authors:  Cherie Conley; Ragan Johnson; Keosha Bond; Sullivan Brem; Jasmine Salas; Schenita Randolph
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

2.  Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project.

Authors:  Jill Blumenthal; Raphael Landovitz; Sonia Jain; Feng He; Ryan Kofron; Eric Ellorin; Gifty M Ntim; Jamila K Stockman; Katya Corado; K Rivet Amico; David J Moore; Sheldon Morris
Journal:  AIDS Patient Care STDS       Date:  2021-12       Impact factor: 5.944

3.  Attitudes and Perceived Barriers to Routine HIV Screening and Provision and Linkage of Postexposure Prophylaxis and Pre-Exposure Prophylaxis Among Graduate Medical Trainees.

Authors:  Jason Zucker; Caroline Carnevale; Deborah Theodore; Delivette Castor; Kathrine Meyers; Jeremy Gold; Daniel Winetsky; Matthew Scherer; Alwyn Cohall; Peter Gordon; Magdalena Sobieszczyk; Susan Olender
Journal:  AIDS Patient Care STDS       Date:  2021-04-23       Impact factor: 5.078

4.  Capturing missed HIV pre-exposure prophylaxis opportunities-sexually transmitted infection diagnoses in the emergency department.

Authors:  Stephanie E Mclaughlin; Farzana Kapadia; Richard E Greene; Robert Pitts
Journal:  Int J STD AIDS       Date:  2021-12-08       Impact factor: 1.456

5.  HIV Risk and Pre-Exposure Prophylaxis Eligibility Among Emergency Department Patients.

Authors:  Jason S Haukoos; Douglas A E White; Sarah E Rowan; Carolynn Lyle; Stephanie Gravitz; Kellie Basham; Ashley Godoy; Kevin Kamis; Emily Hopkins; Erik Anderson
Journal:  AIDS Patient Care STDS       Date:  2021-06       Impact factor: 5.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.